ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

44.40
-0.11
(-0.25%)
Al cierre: 26 Febrero 3:00PM
44.60
0.20
( 0.45% )
Fuera de horario: 5:30PM
Gráfico avanzado

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
44.60
Postura de Compra
44.44
Postura de Venta
44.80
Volume Operado de la Acción
1,218,189
43.97 Rango del Día 46.00
36.52 Rango de 52 semanas 90.62
Capitalización de Mercado [m]
Precio Anterior
44.51
Precio de Apertura
44.9999
Última hora de negociación
17:30:38
Volumen financiero
US$ 54,938,750
Precio Promedio Ponderado
45.0987
Volumen promedio (3 m)
2,194,251
Acciones en circulación
85,774,474
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-36.07
Beneficio por acción (BPA)
-1.79
turnover
371.21M
Beneficio neto
-153.61M

Acerca de CRISPR Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Zug, Che
Fundado
-
CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRSP. The last closing price for CRISPR Therapeutics was US$44.51. Over the last year, CRISPR Therapeutics shares have traded in a share price range of US$ 36.52 to US$ 90.62.

CRISPR Therapeutics currently has 85,774,474 shares in issue. The market capitalisation of CRISPR Therapeutics is US$3.82 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -36.07.

Flujo de Opciones CRISPR Therapeutics (CRSP)

Flujo General

Optimista

Prima Neta

54k

Calls / Puts

600.00%

Comp. / Vent.

16.67%

OTM / ITM

16.67%

Sweeps Ratio

0.00%

CRSP Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-7.72-14.75535168252.3255.8844.02295315649.37075154CS
42.756.5710872162541.8555.8838.28272059445.98835783CS
12-6.79-13.212687293251.3955.8836.52219425144.15447508CS
26-4.55-9.2573753814949.1559.069336.52170486046.14395706CS
52-38.9-46.586826347383.590.6236.52153421052.70439639CS
156-14.97-25.130099043159.5791.136.52153746557.56797753CS
260-5.37-10.746447868749.97220.2132147784277.04664192CS

CRSP - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de CRISPR Therapeutics?
El precio actual de las acciones de CRISPR Therapeutics es US$ 44.60
¿Cuántas acciones de CRISPR Therapeutics están en circulación?
CRISPR Therapeutics tiene 85,774,474 acciones en circulación
¿Cuál es la capitalización de mercado de CRISPR Therapeutics?
La capitalización de mercado de CRISPR Therapeutics es USD 3.82B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de CRISPR Therapeutics?
CRISPR Therapeutics ha negociado en un rango de US$ 36.52 a US$ 90.62 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de CRISPR Therapeutics?
El ratio precio/beneficio de CRISPR Therapeutics es -36.07
¿Cuál es el ratio de efectivo a ventas de CRISPR Therapeutics?
El ratio de efectivo a ventas de CRISPR Therapeutics es 14.93
¿Cuál es la moneda de reporte de CRISPR Therapeutics?
CRISPR Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de CRISPR Therapeutics?
El último ingresos anual de CRISPR Therapeutics es USD 371.21M
¿Cuál es el último beneficio anual de CRISPR Therapeutics?
El último beneficio anual de CRISPR Therapeutics es USD -153.61M
¿Cuál es la dirección registrada de CRISPR Therapeutics?
La dirección registrada de CRISPR Therapeutics es BAARERSTRASSE 14, ZUG, 6300
¿Cuál es la dirección del sitio web de CRISPR Therapeutics?
La dirección del sitio web de CRISPR Therapeutics es www.crisprtx.com
¿En qué sector industrial opera CRISPR Therapeutics?
CRISPR Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ULYUrgent ly Inc
US$ 0.8668
(106.38%)
6.31M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
ROOTRoot Inc
US$ 121.00
(22.58%)
118.53k
DMRCDigimarc Corporation
US$ 20.01
(-26.00%)
39.81k
SYTASiyata Mobile Inc
US$ 3.19
(-23.50%)
495.68k
TNDMTandem Diabetes Care Inc
US$ 27.20
(-19.02%)
310.54k
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
SPGCSacks Parente Golf Inc
US$ 0.5997
(-18.08%)
1.52M
NVDANVIDIA Corporation
US$ 131.00
(-0.21%)
41.88M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M

CRSP Finanzas

Finanzas

CRSP Discussion

Ver más
jondoeuk jondoeuk 5 días hace
Looks pretty bullish for Casgevy https://www.businesswire.com/news/home/20250221469479/en/bluebird-bio-Announces-Definitive-Agreement-to-be-Acquired-by-Carlyle-and-SK-Capital
👍️0
TechandBio TechandBio 1 semana hace
Added a chunk today to my stash average is now 42.00

$CRSP
👍️0
TechandBio TechandBio 1 semana hace
Nice pre market action!

Very deep pipeline with a mega partner VRTX

$CRSP
👍️0
TechandBio TechandBio 2 semanas hace
Starting to turn the corner now!

Glad I re-loaded the low 40's

$CRSP
👍️ 1
jondoeuk jondoeuk 1 mes hace
Anticipated 2025 milestones https://www.globenewswire.com/news-release/2025/01/13/3008308/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2025-Milestones.html
👍️ 1
jondoeuk jondoeuk 1 mes hace
Link to the webcast https://jpmorgan.metameetings.net/events/healthcare25/sessions/58421-crispr-therapeutics/webcast/general_signin?gpu_only=true&kiosk=true+%5Bjpmorgan.metameetings.net%5D
👍️ 1
jondoeuk jondoeuk 2 meses hace
They will present at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 14, at 2:15 PM PST).
👍️ 1
PonkenPlonken PonkenPlonken 3 meses hace
cheap cheap
👍️ 1
jondoeuk jondoeuk 3 meses hace
The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for “mistakes” in how the FDA handled early work for in vivo gene therapies, which “led to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!
👍️0
jondoeuk jondoeuk 3 meses hace
CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.
👍️ 1
PonkenPlonken PonkenPlonken 3 meses hace
so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651
👍️ 1
jondoeuk jondoeuk 3 meses hace
They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.
👍️ 1
jondoeuk jondoeuk 4 meses hace
ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html
👍️0
jondoeuk jondoeuk 4 meses hace
Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
👍️0
Monksdream Monksdream 4 meses hace
CRSP 10Q 11/5
👍️0
Monksdream Monksdream 4 meses hace
CRSP under $50
👍️0
jondoeuk jondoeuk 4 meses hace
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️ 1
TechandBio TechandBio 5 meses hace
CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
👍️0
Monksdream Monksdream 5 meses hace
Buy range again thanks a bunch
👍️0
Monksdream Monksdream 5 meses hace
Buy range again thanks a bunch
👍️0
OldAIMGuy OldAIMGuy 5 meses hace
Hi MD,
Here's a little longer view:


This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG
👍️0
Monksdream Monksdream 5 meses hace
CRSP trend since February remains bearish
👍️0
jondoeuk jondoeuk 7 meses hace
Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html
👍️0
lambchops lambchops 7 meses hace
Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!
👍️0
Monksdream Monksdream 7 meses hace
CRSP under $75
👍️0
TechandBio TechandBio 8 meses hace
Crispr added some $120 Vertical debit spreads in 2026

$CRSP
👍️ 1
axelvento axelvento 9 meses hace
I agree.....solid company$$$$$$$$
👍️0
Monksdream Monksdream 9 meses hace
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero
👍️ 1
axelvento axelvento 10 meses hace
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
👍️0
jondoeuk jondoeuk 10 meses hace
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
👍️0
jondoeuk jondoeuk 10 meses hace
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
👍️0
jondoeuk jondoeuk 10 meses hace
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
👍️0
jondoeuk jondoeuk 10 meses hace
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
👍️0
OldAIMGuy OldAIMGuy 11 meses hace
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
👍️0
OldAIMGuy OldAIMGuy 11 meses hace
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
👍️0
Monksdream Monksdream 11 meses hace
CRSP over $30
👍️0
jondoeuk jondoeuk 11 meses hace
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
👍️0
Monksdream Monksdream 1 año hace
CRSP new 52 week high
👍️0
Monksdream Monksdream 1 año hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 1 año hace
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 1 año hace
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 1 año hace
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
👍️0
jondoeuk jondoeuk 1 año hace
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 1 año hace
Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

👍️0
Monksdream Monksdream 1 año hace
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1
jondoeuk jondoeuk 1 año hace
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 1 año hace
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
👍️0
jondoeuk jondoeuk 1 año hace
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 1 año hace
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
👍️0